Posted 10/18/2007 1:10 PM (GMT 0)
I bet the press release did not explain that Tysabri was pulled from the market, and clinical trials of Crohn's diseases and rheumatoid arthritis were suspended because during the trials two patients (that's people like you and me) developed progressive multifocal leukoencephalopathy. This is a deadly disease of the brain that progressively and fataly demyelinates the central nervous system. It is typically seen in immunosuppressed individuals. How does tysarbi work? By suppressing the immune system. There might be some of us out there so desperately ill that the decision to use tysarbi is warranted, but ...
The problem with all these new drugs is that they all have their proponents -- drug companies with huge investments -- who are sometimes less willing to give consumers the straight story. Crohn's patients live with the knowledge that they will have to play dodge the bullet with medications over the lifetime of their illness. We can only make the decisions that are best for us if we have all the facts.
For my money, rather than jump on the bandwagon and push to get to the front of the line to get every new drug that comes on the market, my plan is to stick -- as much as possible -- with the older classes of medications whose track records have been established.